[225Ac]Ac-PSMA-617 and rechallenge [177Lu]Lu-PSMA-617 evaluated against chemotherapy in mCRPC.
Evaluation of [225Ac]Ac-PSMA-617 vis-a-vis Rechallenge [177Lu]Lu-PSMA-617 PRLT Versus Cabazitaxel or Oral Metronomic Chemotherapy in mCRPC: An Observational Analysis of Outcome and Toxicity Profiles in a Real-World Clinical Scenario.
Background
Metastatic castration-resistant prostate cancer (mCRPC) represents an aggressive disease state where existing therapies often yield limited success. Patients typically progress after androgen receptor pathway inhibitors and docetaxel chemotherapy, necessitating further treatment options. Prostate-specific membrane antigen (PSMA)-targeted radioligand therapy (PRLT), using isotopes like [177Lu]Lu-PSMA-617, has emerged as a promising theranostic strategy. However, disease progression still occurs, prompting the need to explore alternative or sequential treatments, including alpha-emitters like [225Ac]Ac-PSMA-617 or different chemotherapy regimens, to improve patient outcomes and manage toxicity.